Kinnate Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Kinnate Biopharma

11/05/2023 22:33

* Kinnate Biopharma Inc  KNTE.OQ  reported a quarterly
adjusted
loss of 73 cents​​ per share for the quarter ended in March. The
mean expectation of eight analysts for the quarter was for a
loss of 73 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kinnate Biopharma Inc's reported EPS for the quarter was a
loss
of 73 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Kinnate Biopharma Inc shares had fallen by 44.3% this
quarter and lost 43.0% so far this year.
    * The company reported a quarterly loss of $32.94 million.
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $22.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:33 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.73          -0.73          Met
 Dec. 31 2022      -0.72          -0.72          Met
 Sep. 30 2022      -0.61          -0.70          Missed
 Jun. 30 2022      -0.64          -0.62          Beat